Virax Biolabs Group Ltd 6-K Filing
Ticker: VRAX · Form: 6-K · Filed: Dec 4, 2025 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2025 |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $5,000,000, b, $0.001, $0.3999, $0.50, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Virax Biolabs Group Ltd (ticker: VRAX) to the SEC on Dec 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $5,000,000, b (the Company received gross proceeds of $5,000,000, before deducting placement agent fees and); $0.001 (e 12,500,000 ordinary shares, par value $0.001 per share, of the Company (the “); $0.3999 (Options”) at a purchase price of $0.3999 per Pre-Funded Warrant and associated P); $0.50 (rchase up to 875,000 Ordinary Shares at $0.50 per share to H.C. Wainwright & Co., pla); $0.0001 (nded Warrants have an exercise price of $0.0001 per share, may be exercised commencing).
How long is this filing?
Virax Biolabs Group Ltd's 6-K filing is 4 pages with approximately 1,267 words. Estimated reading time is 5 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,267 words · 5 min read · ~4 pages · Grade level 14.1 · Accepted 2025-12-04 16:07:11
Key Financial Figures
- $5,000,000, b — the Company received gross proceeds of $5,000,000, before deducting placement agent fees and
- $0.001 — e 12,500,000 ordinary shares, par value $0.001 per share, of the Company (the “
- $0.3999 — Options”) at a purchase price of $0.3999 per Pre-Funded Warrant and associated P
- $0.50 — rchase up to 875,000 Ordinary Shares at $0.50 per share to H.C. Wainwright & Co., pla
- $0.0001 — nded Warrants have an exercise price of $0.0001 per share, may be exercised commencing
- $0.40 — erred Options have an exercise price of $0.40 per Ordinary Share and will be exercisa
- $2.934 — arch 2023 and have an exercise price of $2.934 per share were amended simultaneously w
Filing Documents
- 6-k_dec_2025_pipe.htm (6-K) — 48KB
- vrax-ex10_1.htm (EX-10.1) — 370KB
- vrax-ex10_2.htm (EX-10.2) — 232KB
- vrax-ex10_3.htm (EX-10.3) — 156KB
- vrax-ex10_4.htm (EX-10.4) — 167KB
- vrax-ex10_5.htm (EX-10.5) — 167KB
- vrax-ex99_1.htm (EX-99.1) — 17KB
- vrax-ex99_2.htm (EX-99.2) — 18KB
- 0001193125-25-308079.txt ( ) — 1177KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: December 4, 2025 By: /s/ James Foster James Foster, Chief Executive Officer